Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2010

View Archived Issues

PK/PD modeling of siltuximab predicts clinically feasible dosing regimen

Nycomed claims novel phosphodiesterase 5 inhibitors

BFPT-2603 safe and efficacious in monkey model of allergic asthma

Ulipristal noninferior to levonorgestrel for emergency contraception

Denosumab shows therapeutic activity in giant-cell tumor of bone

NicOx discloses novel nitric oxide-releasing steroids

Eisai discovers novel JNK3 kinase inhibitors

Dual M3 antagonists/beta2-adrenoceptor agonists claimed by Argenta and AstraZeneca

Genta raises funds for advancement Genasense and tesetaxel

Isis earns milestone payment from Bristol-Myers for BMS-PCSK9Rx

MDS Foundation comments on NICE's decision against Vidaza

Summit claims novel upregulators of endogenous utrophin

Roche and Biogen place ocrelizumab rheumatoid arthritis program on hold

Auxilium launches Xiaflex in U.S. for treatment of Dupuytren's contracture

Genmab reports phase III results on zalutumumab in refractory head and neck cancer

Nabi and GSK close NicVAX option and license agreement

Novavax completes enrollment in pivotal H1N1 flu vaccine trial

XenoPort to focus on key later-stage product candidates

FDA approves NDA for Alza's Exalgo for pain management

Nektar Therapeutics presents phase II data on NKTR-102 in platinum-resistant ovarian cancer

ExonHit and bioMerieux terminate colon cancer collaboration

Advaxis confirms long-term stability ADXS11-001 cancer vaccine

Mologen's phase II IMPACT trial of MGN-1703 in cancer approved in Germany and Austria

FDA and EMA grant orphan drug status to ImmunoGen's IMGN-901 in MCC

New neuraminidase inhibitor CS-8958 shows promise in preclinical and clinical evaluation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...